Trial reportEuropean archives of psychiatry and clinical neuroscience2011
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
Trial report in European archives of psychiatry and clinical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00856583 (Sertindole Versus Risperidone Safety Outcome Study), which is not on this map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects.Clinical drug investigation · 2021Pooled it
- Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.The Cochrane database of systematic reviews · 2021 · on this mapPooled it
- Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Physical health care monitoring for people with serious mental illness.The Cochrane database of systematic reviews · 2014Pooled it
- Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2022Article
- Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.Neuropsychiatric disease and treatment · 2019Article
- Medications that cause weight gain and alternatives in Canada: a narrative review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Review
- A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2013Article
- Review
- [Psychotropic drugs and diabetes].Wiener medizinische Wochenschrift (1946) · 2011Review
- Obesity and coronary risk in patients treated with second-generation antipsychotics.European archives of psychiatry and clinical neuroscience · 2011Article
- Pain, affect and psychotic illness.European archives of psychiatry and clinical neuroscience · 2011Article
- Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. The short- and long-term metabolic safety of sertindole was compared to that of risperidone in a subset of patients enrolled in the sertindole cohort prospective (SCoP) study, an open randomized study. In 261 randomized patients, there were moderate increases in mean weight, BMI, and waist circumference during treatment with either sertindole or risperidone; after 12 weeks, the increase in weight was 1.3 and 1.1 kg, respectively, and after 36 weeks, it was 2.2 and 2.0 kg, respectively. From baseline to last assessment (up to 60 weeks), weight gains of 1.8 and 1.7 kg for sertindole and risperidone, respectively, were observed. Similar proportions of patients (sertindole: 17% versus risperidone: 16%) had weight increases ≥7% from baseline to last assessment. The mean changes from baseline in triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, plasma glucose and blood pressure were small and not clinically relevant in both treatment groups. No patient in either of the groups developed type 2 diabetes during the study. At last assessment, the prevalence of metabolic syndrome (International Diabetes Federation) was 17% in the sertindole group and 26% in the risperidone group and the incidence of metabolic syndrome was 7% in the sertindole group and 10% in the risperidone group. Treatment with either sertindole or risperidone did not appear to be associated with an increased comparative risk of developing metabolic syndrome. In general, the metabolic effects of sertindole and risperidone were similar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.